People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among 120 women with overweight or obesity, MHT users lost 19.18% of their total body weight with tirzepatide (Mounjaro, ...

In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

EXPERTS have revealed there could be a ‘golden dose’ of Mounjaro that helps shift the most weight – and it’s not the highest ...

Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...